ARTICLE | Clinical News

Ornithine phenylacetate: Ph IIa STOP-ALF data

December 2, 2016 4:43 PM UTC

Data from 36 evaluable patients with minimal renal dysfunction or with compromised renal function in the open-label, U.S. Phase IIa STOP-ALF trial showed that IV OCR-002 given for up to 5 days was well tolerated at all doses (3.33-20 g/24 hours), with no treatment-related serious adverse events reported. Ocera said the highest dose of OCR-002 achieved therapeutic serum levels of phenylacetate and "appeared to result in considerable ammonia excretion in urine as phenylacetylglutamine." Data were presented at the American Association for the Study of Liver Diseases meeting in Boston...

BCIQ Company Profiles

Ocera Therapeutics Inc.